The Least Imperfect Device Karen Meade Clinical Nurse Specialist The Hillingdon Hospital.

Slides:



Advertisements
Similar presentations
Inhalers The Perfect technique Vicky Walker Clinical Lead for Respiratory Services Sarah Wilson Respiratory Nurse Specialist.
Advertisements

Asthma Medication Administration Marcia Winston, MSN,CPNP,AE-C The Children’s Hospital of Philadelphia Division of Pulmonary Medicine.
Steps to better asthma care A guide for primary care.
Respiratory Prescribing in Tower Hamlets Bill Sandhu Head of Medicines Management, Tower Hamlets Medicines Management Team.
Respiratory Measurement and Treatment Gail M. Maier, Ph.D., R.N. Associate Director, ED&R The Ohio State University Wexner Medical Center Peak Flow and.
Respiratory Prescribing
Long-term Controller Asthma Medications
Inhaler technique is it important?. Compton et al (2006) Review of evidence from 6 European countries ( Spain, Italy, France, Germany, Netherlands, UK)
Improving Medication Adherence in COPD with an Effective Device Orapan Poachanukoon, MD.
Perform and therapeutic benefit of Using a Nebuliser / Inhaler correctly Devangna Bhatia.
InhalersInhalers How They Work and What They Do For You By: Lauren Coe.
Asthma in Schools A MacRobbie January What is Asthma ? Asthma is a problem with breathing - it affects the airways which are the small tubes which.
Paediatric Asthma Maria Tracey Paediatric Pharmacist Jane Davis Paediatric Clinical Nurse Specialist CF/Respiratory Royal Alexandra Hospital Paisley.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Karen Homan NHS Bedfordshire
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
MANAGEMENT OF ASTHMA 6 Penaflor, Dominic Quinto, Milraam Ramos,Josefa Victoria Sicat, Gracie Suaco, David Tio- Cuizon, Jeremiah Valenzuela, Virginia Lou.
Management of patients with allergic disorders. ASTHMA MANAGEMENT.
Mosby items and derived items © 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 3 Administration of Aerosolized Agents.
Aerosol Therapy and Nebulizers
Metered Dose Inhalers (MDIs)
David P. Arpino, RRT, RPFT ALHE 4060 – Research in Allied Health Dr. Masini August 2, 2007.
Inhalation Devices Heba Abd El-fattah Sabry Pharm D.
SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£
Inhaled Therapeutics using Dry Powder Inhalers (DPI) Scott Selig ‘19 Biomedical Engineering.
Aerosols Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Asthma Medication and Devices Update Lisa C. Johnson RRT, RCP, BAS, AE-C Pediatric Asthma Program Vidant Medical Center.
1 Asthma. 2 Disease of the airways that carry air in and out of the lungs Asthma causes: –Airways to narrow –Lining to swell –Cells to produce more mucus.
Responsible Respiratory Prescribing
Severe breathlessness
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Common Respiratory Therapy Drugs. How Administered Small Volume Nebulizer (SVN) (2:45-3:45)Small Volume Nebulizer (SVN) Breathe medicated mist over several.
1 © 2013 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part, except for use as permitted in a license.
Inhaler technique in COPD management: The cost of getting it wrong Zinc code: UKACL1878da Date of preparation May 2015 AstraZeneca provided funding & reviewed.
Aerosol Delivery Devices and Peak Flowmeters
Wendy Pigg Practice support Pharmacist/Independent Prescriber
Areas to cover Analysis of information Recruitment Review.
YOUR PHARMACY / JOB- TITLE YOUR NAME Respiratory MUR.
Lynn Helliwell.
MDI market analysis and cost comparison in Hungary Róbert Tóth Ministry of Environment and Water Budapest, Hungary.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
COMMON ERRORS IN MANAGEMENT OF BRONCHIAL ASTHMA IN A PERIPHERAL HOSPITAL Surgeon Cdr Anuj Singhal Graded Specialist (Med)
Taper DPI FeatureImpact Efficacy Safety Compliance Cost High Efficiency  Equivalent lung dose achieved in- vitro with approximately 50% lower delivered.
Lesley Williams, Victoria Velasco, Dan Heyworth & Lisa Bradley 3M Health Care Ltd, Up Brooks, Clitheroe, Lancashire, BB7 1NX, England 3 Drug Delivery Systems.
Respiratory Health Asthma and COPD. Definition of asthma 2 Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation.
Asthma and Small Airway Inflammation
Medicines Optimisation
Inhaler Technique & PEFR
Research where it is most needed National Respiratory Strategy
COPD PATHWAY AND PRESCRIBING POLICY IN LAMA options (stop SAMA):
Devices, demonstration and discussion
Monitoring asthma in primary care
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Improving Inhaler Technique
Aerosol Therapy & HFNC Natalie Napolitano, MPH, RRT-NPS, FAARC
Medicines Optimisation
Unlocking the Secrets to Maximize Pulmonary Medications
Chapter 3 Administration of Aerosolized Agents
Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.
The Aerosol Drug Management Improvement Team
INHALATION THERAPY FOR ASTHMA AND COPD
AEROSOL THERAPY.
INHALATION THERAPY FOR ASTHMA AND COPD
Determination of the preferred tongue position for optimal inhaler use
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
Presentation transcript:

The Least Imperfect Device Karen Meade Clinical Nurse Specialist The Hillingdon Hospital

The Development of Inhalers 1956 first pMDI 1968 first DPI (Sodium Cromoglycate) 1974 first breath actuated device 1977 first single dose DPI 1980 first large volume spacer 1988 first multi-dose DPI 1998 combination inhalers On-going transition to CFC free pMDI’s Snell (1995)

Why Use Inhalers? n Rapid action n Smaller doses Fewer side effects Fewer side effects Pauwels 1993, Ariyananda et al 1995

Why is the device important ? Efficacy of treatment depends on; n Physical factors n Mode of inhalation n Patency of airways n Patient compliance n Patient ability Ariyananda et al 1995, Weller 1999, DTB 2000, Lenney et al 2000

Characteristics of the Ideal Device - 1 n reliability & reproducibly delivers a predetermined dose of drug n easy to use n cost effective n portable n easy to assess technique n low oropharangeal deposition n available in a range of therapies

Characteristics of the Ideal Device - 2 n suits all settings n integral cap / cover n dose counter / able to tell when empty n environmentally friendly n available in primary, secondary & tertiary care n easy to identify preventer/reliever Raine & Newberry 1991, Hanley 1995, Hobbs 1995, NARTC 1997, DTB 2000

Main device types n Aerosol –Pressurised metered dose inhaler (pMDI) –Breath actuated n Dry powder (breath actuated) inhalers –Turbohaler –Accuhaler –Diskus –Clickhaler –Diskhaler –Rotahaler

Pressurised Metered Dose Inhalers (pMDI)

Beclomethasone 50 Beclomethasone 250 Beclozone easi breathe 250 Beclomethasone (QVAR)100 Beclomethasone (QVAR) 50 Metered dose inhaler devices

Metered dose inhalers - pMDI Metered dose inhalers - pMDI 7-20% drug delivery + range of therapies + cheap + portable Leech(1998), DTB(2000), NARTC(1997) - need co-ordination - no dose counter except in combined medications - oro-pharangeal deposition - cold freon effect

Spacer devices – large and small volume spacer devices

Spacers 15-30% drug delivery + reduce oral deposition + tidal breathing acceptable/suitable for during an attack + suitable from birth - wide variation in drug delivery between spacers - bulky DTB(2000), NARTC(1997), Hobbs(1995)

Breath Actuated MDI’s – “Easibreathe and Autohaler”

Breath Actuated MDI’s 15-20% drug delivery + portable + no co-ordination required + lower inspiratory flow required (20- 30L/min) - no dose counter - no LA ß2-agonist - patient may block vents DTB(2000), NARTC (1997), Hobbs(1995)

Dry Powder Inhalers - General points + portable + CFC free + dose counter + breath actuated + suitable for 6+yrs - need higher inspiratory flows - some susceptible to damp NARTC (1997), DTB (2000)

Clickhaler

Clickhaler 10-15% drug delivery + low inspiratory flow (15 L/min) + locks when empty - powder can fall out! - no LA ß2 agonist DTB(2000)

Rotahaler, Spinhaler, Diskhaler, Aerohaler

15% drug delivery + compact +/- taste + able to monitor doses - require reloading - loss of powder - capsule can deteriorate DTB(2000), NARTC(1997), Hobbs(1995)

Handihaler + low inspiratory flow + once a day dosing + audible noise when using it correctly - only available in Tiotropium - needs reloading - susceptible to damp

Accuhaler

Accuhaler 16-21% drug delivery + range of therapies + locks when empty + combination therapy + low inspiratory flow 30-90L/min - requires monthly replacement (60 doses) DTB(2000), NARTC(1997)

Turbohaler

Turbohaler Inhaler devices n Bricanyl, (Terbutaline) n Pulmicort, (Budesonide) n Oxis, (Eformoterol) n Symbicort, 100/6, 200/6, 400/12

Turbohaler 20-30% drug delivery + range of therapies + visible warning when 20 doses left +/- no taste + inspiratory flow L/min - susceptible to damp DTB(2000), NARTC(1997), Hanley(1995)

Patient Preference Studies n Subjective measure n Preference does not correlate with technique n Small studies n Bias n Not reproducible (Hanley 1995, Raine et al 1991, Lenney et al 200, Williams 1995)

Choosing the ‘least imperfect’ device n Drugs required i.e. ß2, ICS, LAß2 n devices available n patient able to demonstrate a good technique & health professional able to check technique n suits all settings n device acceptable to the patient

Checking Technique n Visual check with placebo n Independent check n Inspiratory flow check

Inhaler & Spacer Care n Rinse through MDI’s n Wash spacer once a month & drip dry n Remember to dry well before using n Replace spacer every 6 months n Do not leave DPI in damp environments n Write start date on MDI & expected finish date

The Least Imperfect Device ? The device which the patient can, & will use

Thank you Any questions ?